Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
FAK-JAK 2 dual Inhib
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Teva
Drug class:
JAK2 inhibitor, FAK inhibitor
Related drugs:
‹
entrectinib (178)
ruxolitinib (73)
AZD1480 (5)
CHZ868 (4)
pacritinib (3)
CEP-701 (3)
AZ 960 (2)
fedratinib (2)
momelotinib (2)
JSI-124 (2)
TG02 (2)
EC-70124 (1)
tofacitinib (1)
R 723 (0)
TG101209 (0)
flonoltinib (0)
LY 2784544 (0)
BS-HH-002.SA (0)
AG 490 (0)
VS-6063 (8)
LY294002 (7)
AZD0530 (7)
VS-4718 (5)
APG-2449 (4)
IN10018 (3)
GSK2256098 (1)
PF-562271 (1)
SY-707 (1)
CEP-37440 (0)
NVP-TAE226 (0)
PF-573228 (0)
entrectinib (178)
ruxolitinib (73)
AZD1480 (5)
CHZ868 (4)
pacritinib (3)
CEP-701 (3)
AZ 960 (2)
fedratinib (2)
momelotinib (2)
JSI-124 (2)
TG02 (2)
EC-70124 (1)
tofacitinib (1)
R 723 (0)
TG101209 (0)
flonoltinib (0)
LY 2784544 (0)
BS-HH-002.SA (0)
AG 490 (0)
VS-6063 (8)
LY294002 (7)
AZD0530 (7)
VS-4718 (5)
APG-2449 (4)
IN10018 (3)
GSK2256098 (1)
PF-562271 (1)
SY-707 (1)
CEP-37440 (0)
NVP-TAE226 (0)
PF-573228 (0)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login